Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?

Co-Diagnostics Inc (NASDAQ:CODX) (Co-Dx) has announced that it will be disclosing the global expansion of its original equipment manufacturer (OEM) agreement with Bio Molecular Systems (BMS) at the company's customer and distributor update today at the American Association for Clinical Chemistry's (AACC) Annual Scientific Meeting & Clinical Lab Expo. The molecular diagnostics firm said the expanded branding and distribution OEM agreement increases Co-Diagnostics' approved sales territories to 193 countries worldwide.

Co-Diagnostics set to expand OEM deal with Bio Molecular Systems at AACC expo

SALT LAKE CITY , July 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing the original Rotor-Gene Real-Time PCR instrument, with a reputation for expertise in developing innovative, versatile, robust, and easy-to-use products.

Co-Diagnostics, Inc. to Announce Expansion of OEM Agreement with Bio Molecular Systems at AACC

The Company will also be providing an update to its distributors and other customers on July 26 at 11 am CT. SALT LAKE CITY , July 20, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth to showcase its existing and upcoming suite of diagnostics products and technology applications at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, held July 24-28 at the McCormick Place Convention Center in Chicago, IL, in addition to providing an update for its worldwide network of customers and distributors.

Co-Diagnostics, Inc. to Host Booth at AACC Held July 24-28 in Chicago

CODX stock is up during early afternoon trading as Co-Diagnostics ships out monkeypox testing reagents to help deal with the outbreak. The post CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests appeared first on InvestorPlace.

CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests

The medical test maker just got its new test for monkeypox out the door for the first time.

Why Co-Diagnostics Stock Is Rising Today

Co-Diagnostics (NASDAQ:CODX) Inc announced it has shipped testing reagents for the monkeypox virus, currently exhibiting a multi-country outbreak, to one of its international distributors. In a statement, the molecular diagnostics company said the products shipped were designed and developed on an expedited basis to meet the demands in the distributor's region.

Co-Diagnostics ships monkeypox virus tests to international distributor to fight multi-country outbreak

SALT LAKE CITY , July 11, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak to one of its international distributors. According to the World Health Organization (WHO), monkeypox is a virus originally transmitted to humans from animals, and then transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding.

Co-Diagnostics, Inc. Announces Shipment of Monkeypox Virus Test

Investors in the diagnostics and research outfit received a dose of beneficial news today.

Why Co-Diagnostics Is Running Higher Today

SALT LAKE CITY , June 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th International Biodetection Technologies Conference, held virtually June 28-29, 2022. The Biodetection Technologies Conference is an internationally recognized meeting for experts in detection & identification of biological threats, which this year plans to address the key topics in detection and present the latest R&D and technological innovation in ready-to-market systems.

Co-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual Conference

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?

SALT LAKE CITY , June 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Summer Small Cap Virtual Investor Conference June 15-16, 2022. The presentation will begin at 3:15 p.m.

Co-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference

SALT LAKE CITY , June 9, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 22nd MEDEXPO Africa 2022, held June 9-11 in Nairobi, Kenya. The largest international medical trade exhibition in the country features exhibitors from over 30 countries, all profiling innovative solutions from leaders in the medical technology industry, and targeted toward buyers from across the continent seeking new products, equipment, machinery, services and solutions.

Co-Diagnostics, Inc. to Host Booth at MEDEXPO Africa 2022 in Nairobi, Kenya on June 9-11

The company is not monkeying around with the latest possible global health menace.

Why Co-Diagnostics Trounced the Market on Thursday

Co-Diagnostics (NASDAQ:CODX) Inc, a molecular diagnostics company, has completed the principal design work on a PCR test for the monkeypox virus, the company announced.  Outbreaks of the virus have been reported in roughly 20 countries (primarily in Europe) where it is not endemic, with more than 200 confirmed or suspected infections, according to reporting from Reuters and others.

Co-Diagnostics develops principal design work on monkeypox PCR test

SALT LAKE CITY , May 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak. According to the World Health Organization (WHO), monkeypox is a virus originally transmitted to humans from animals, and then transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding.

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 2022 Global Investment Conference, being held in-person and virtually on May 23-26 in Miami, Florida.

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Andrew Benson - Head, IR Dwight Egan - Chairman, CEO & President Brian Brown - CFO & Company Secretary Conference Call Participants Yi Chen - H.C. Wainwright & Co. James Sidoti - Sidoti & Company Theodore O'Neill - Litchfield Hills Research Operator Good day, and welcome to the Co-Diagnostics Inc. First Quarter 2022 Earnings Results Conference Call.

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q1 2022 Results - Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 44.44% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Q1 Earnings and Revenues Beat Estimates

Co-Diagnostics (NASDAQ:CODX) Inc has reported record 1Q revenue as the company says it plans to leverage its strong financial position to fund future growth initiatives. For the quarter ending March 31, 2022, the company reported revenue of $22.7 million, up from $20 million for the same quarter in 2021, which it attributed primarily to sales of its Logix Smart COVID-19 test.

Co-Diagnostics reports record 1Q revenue as company looks to expand into new markets and innovative molecular diagnostics solutions

Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY , May 12, 2022 /PRNewswire/ --  Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the first quarter ended March 31, 2022. Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 First-Quarter 2022 Financial Results: Revenue of $22.7 million, primarily due to sales of the Logix Smart™ COVID-19 Test Gross profit increased to $19.4 million, representing 85.5% of consolidated revenue Operating income of $9.8 million compared to $10.3 million a year ago, due to an increase in research and development expense Income before taxes of $13.1 million Net income of $11.7 million, compared to a net income of $7.9 million in the prior-year first quarter, representing $0.34 per fully diluted share Adjusted EBITDA of $11.4 million Cash, cash equivalents, and marketable securities totaled $97.4 million as of March 31, 2022, an increase of $7.5 million from December 31, 2021 "We are incredibly proud to deliver another solid quarter of growth following our record results in 2021," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.

Co-Diagnostics Reports Solid First Quarter 2022 Financial Results

SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the Medical Fair Brasil, held May 3-6, 2022, at the Expo Center Norte in São Paulo, Brazil. The international exhibition on hospital, diagnostic, pharmaceutical, medical and rehabilitation equipment and supplies is described on its website as a communication channel with the healthcare sector where companies present their products, innovations and services with the purpose of supplying and transforming the healthcare chain.

Co-Diagnostics, Inc. to Host Booth at Medical Fair Brasil 2022 in São Paulo on May 3-6

CoDiagnostics, Inc. (CODX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for CoDiagnostics, Inc. (CODX)

SALT LAKE CITY , April 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held April 23-26, 2022, in Lisbon, Portugal. The congress, which brings together experts from clinical microbiology and infectious disease fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues, will also feature a hybrid format for the first time, to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities.

Co-Diagnostics, Inc. to Host Booth at ECCMID 2022 in Lisbon, Portugal on April 23-26

Co-Diagnostics (NASDAQ:CODX) has said that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAQ Hepatitis C (HCV) Viral Load Kit as an in vitro diagnostic (IVD). CoSara's new real-time HCV PCR test is built on the company's patented CoPrimer technology and designed to be used as an aid in assessing response to antiviral treatments in patients diagnosed with HCV, a disease with no effective vaccine that leads to nearly 300,000 deaths in 2019 according to the World Health Organization (WHO).

Co-Diagnostics says its CoSara Diagnostics Indian joint venture has received clearance to manufacture and sell its Hepatitis C Viral (HCV) Load Kit as an in vitro diagnostic

News for Co-Diagnostics Stock (CODX)